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Perspective
Estimating the Global Burden of Snakebite 
Can Help To Improve Management
Jean-Philippe Chippaux
Lack of Antivenom: A Market 
Failure
Snakebite is a common medical 
emergency in developing countries 
in tropical regions. The only specific 
treatment is antivenom [1], but this 
is often unavailable in remote health 
centres, due to market failure [2,3]. 
In the 1980s in Africa, 150,000 to 
200,000 doses of antivenom were sold 
annually, whereas current sales have 
fallen to less than 20,000 doses per 
year. The price of a vial of antivenom 
has risen by a multiple of 10 over 
the last 20 years. Today, with the 
global economic crisis, the treatment 
represents several months of the 
average income of rural families. 
In an emergency situation, there is 
insufficient time for families to sell 
their crops and livestock to buy the 
antivenom.
The main reasons that the antivenom 
manufacturers use to justify such 
a dramatic price increase are the 
complexity and cost of antivenom 
production. But there are three other 
reasons for the escalating costs. First, 
the antivenom market is unstable. 
Second, there is little financial 
incentive for pharmacists and health 
centres to sell antivenom because 
they reap only feeble profit margins. 
Finally, there are no comprehensive 
data on how many doses of antivenom 
are required and where they should be 
distributed.
Estimating the Global Burden
The first assessment of global 
snakebite incidence and mortality was 
undertaken by Swaroop and Grab in 
1954 [4]. They estimated the number 
of snakebites (in fact envenomings at 
that time) and deaths respectively at 
500,000 and 30,000–40,000 per year 
(their estimates excluded China, USSR, 
and central European countries, from 
which data were unavailable). These 
figures certainly underestimated the 
true burden because Swaroop and Grab 
lacked relevant information for their 
assessment. The second assessment, 
which I published in 1998, was based 
on a greater number of publications 
and so was more reliable, but many 
information gaps remained, including 
the question of how representative 
the local studies were of the wider 
epidemiological situation [5]. Despite 
these gaps, it has generally been 
assumed that there are about 5 million 
snakebites worldwide each year, leading 
to 125,000 deaths.
In this issue of PLoS Medicine, H. 
Janaka de Silva and colleagues report 
on a new estimate of the worldwide 
morbidity and mortality of snakebite, 
using a more thorough and rigorous 
search for data [6]. The researchers 
obtained primary data in three ways: 
(1) searching for publications on 
snakebite, (2) extraction of country-
specific mortality data from databases 
maintained by United Nations 
organizations, and (3) identification of 
grey literature by discussion with key 
informants. Their new study confirms 
that morbidity and mortality due to 
snakebite are very high. The annual 
number of snakebites could be as high 
as 5.5 million, and deaths could range 
from 20,000 to 94,000. These estimates 
have a wide interval because of the 
limitations of the sources used and 
uncertainties about the primary data.
Limitations in Epidemiological 
Research on Snakebite
Reporting of snakebite—and particularly 
envenoming—by health authorities is 
generally very poor in most developing 
countries. To evaluate snakebite 
incidence and mortality, researchers 
therefore rely upon systematic reviews 
of the medical literature. Most of the 
current, accessible primary studies 
use the basic method of retrospective 
compilation of hospital registers 
or statistics from medical services. 
Primary data may also be obtained 
from prospective surveys, which can 
give better information on symptoms, 
complications, or effectiveness of 
treatment, but such surveys take longer 
and are more expensive. 
However, both types of health 
centre surveys—retrospective and 
prospective—only account for a 
proportion of all snakebites, since some 
patients fail to attend health centres. 
And in developing countries, most 
patients (60%–80%) who do arrive at 
health centres with snakebite do so 
after a considerable delay (sometimes 
several days after the bite) because they 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Kasturiratne A, Wickremasinghe AR, de 
Silva N, Gunawardena NK, Pathmeswaran 
A, et al. (2008) Estimating the global 
burden of snakebite: A literature analysis. 
PLoS Med 5(11): e218. doi:10.1371/
journal.pmed.0050218
H. Janaka de Silva and colleagues 
estimate that globally at least 421,000 
envenomings and 20,000 deaths occur 
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first attend a traditional healer. Delay 
in attending health centres has been 
well documented in Africa [3,7,8], and 
to a lesser extent in Asia [9,10] and 
Latin America [11,12]. 
One may assume that some snakebite 
victims die before reaching the 
health centre in due time (leading 
to underestimation of snakebite 
mortality), and others do not go to 
the health centre because they were 
cured (leading to underestimation of 
morbidity). Nevertheless, complications 
of snakebite leading to serious 
sequelae (amputations or neurologic 
deficits) are common. Certainly, 
snakebite morbidity is more likely to be 
underestimated than mortality because 
death is a less frequent outcome 
and probably better reported than 
envenoming.
An alternative study methodology 
uses household surveys to question a 
representative part of the population 
to estimate the incidence and mortality 
of snakebite in the community. This 
technique, recently validated by 
prospective follow-up of populations 
that confirmed its reliability [13], 
is a good complement to hospital 
surveys. However, although household 
snakebite surveys can be valuable and 
informative in helping to plan the 
community’s need for antivenom, this 
method is not yet well developed. 
In the new study by de Silva and 
colleagues, the data were obtained 
from a limited number of studies, 
which were local and scattered. The 
main limitation of their study, as for 
similar types of evaluation, is the 
concern about how representative 
it is of the actual epidemiological 
situation. In my own 1998 study [5], I 
estimated that these local surveys were 
fairly representative, but de Silva and 
colleagues believe that they are not. 
They argue that my assumption was 
undoubtedly too optimistic. Let’s hope 
that de Silva and colleagues’ study 
will encourage clinicians and health 
authorities to report snakebite cases 
and deaths more accurately.
Making Antivenom More 
Accessible
A better knowledge of morbidity and 
mortality due to snakebite would 
lead to improved management, and 
it may reduce the case fatality rate 
and mortality (though perhaps not 
the incidence). Armed with better 
information on the global burden of 
snakebite, antivenom manufacturers 
would be able to better regulate 
production, and medical authorities 
could distribute antivenoms to where 
they are most useful and needed. In 
order to obtain better knowledge on 
snakebite morbidity and mortality, 
we need to standardize methods 
for collecting data, including well-
designed hospital and household 
surveys. De Silva and colleagues’ study 
is a preliminary, but essential, step in 
improving accessibility of antivenoms 
and the treatment of snakebite.  
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